(J Am Heart Assoc. 2016;5:e004075 doi: [10.1161/JAHA.116.004075](10.1161/JAHA.116.004075))
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Introduction {#jah31743-sec-0005}
============

Atrial fibrillation (AF) is a common arrhythmia and a potent risk factor for cardiogenic embolism.[1](#jah31743-bib-0001){ref-type="ref"}, [2](#jah31743-bib-0002){ref-type="ref"} Hypertension is also a common disease and the most frequent comorbidity in patients with AF.[3](#jah31743-bib-0003){ref-type="ref"}, [4](#jah31743-bib-0004){ref-type="ref"} Since hypertension is one of the risk factors for thromboembolism and hemorrhagic complications in patients with AF, it is a component of the CHADS~2~ (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and history of stroke or transient ischemic attack \[TIA\]),[5](#jah31743-bib-0005){ref-type="ref"} the CHA~2~DS~2~‐VASc (CHADS~2~ components, plus vascular disease \[coronary artery disease\], age 65--74 years, and female sex),[6](#jah31743-bib-0006){ref-type="ref"} and the HAS‐BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio \[INR\], elderly \[\>65 years\], drugs/alcohol concomitantly)[7](#jah31743-bib-0007){ref-type="ref"} scores. However, hypertension is not always detected as an independent predictor of thromboembolism or hemorrhagic complications.[8](#jah31743-bib-0008){ref-type="ref"}, [9](#jah31743-bib-0009){ref-type="ref"}, [10](#jah31743-bib-0010){ref-type="ref"}, [11](#jah31743-bib-0011){ref-type="ref"}, [12](#jah31743-bib-0012){ref-type="ref"} In patients with nonvalvular AF (NVAF) who were not receiving anticoagulation therapy, hypertension was an independent risk factor for ischemic stroke.[13](#jah31743-bib-0013){ref-type="ref"} By contrast, the presence of hypertension at baseline was not a significant risk factor for thromboembolism or major hemorrhage in NVAF patients when including those treated with warfarin.[14](#jah31743-bib-0014){ref-type="ref"}, [15](#jah31743-bib-0015){ref-type="ref"} Differences in patient characteristics may have contributed to these inconsistent results. Another possible explanation for the inconsistent results was that blood pressure (BP) control was not considered when a history of hypertension was selected as an explanatory variable for multivariate analysis. The association between BP values and the event incidence has not been elucidated in patients with NVAF in any previous report of the J‐RHYTHM Registry.[14](#jah31743-bib-0014){ref-type="ref"}, [15](#jah31743-bib-0015){ref-type="ref"}, [16](#jah31743-bib-0016){ref-type="ref"}, [17](#jah31743-bib-0017){ref-type="ref"}, [18](#jah31743-bib-0018){ref-type="ref"}, [19](#jah31743-bib-0019){ref-type="ref"}, [20](#jah31743-bib-0020){ref-type="ref"} Therefore, in order to investigate the influence of BP control rather than hypertension on event rates of thromboembolism and major hemorrhage, a post hoc analysis was performed using quartiles of BP values at the time of enrollment and at the time closest to these events in the J‐RHYTHM Registry.

Methods {#jah31743-sec-0006}
=======

Study Design of the J‐RHYTHM Registry {#jah31743-sec-0007}
-------------------------------------

The J‐RHYTHM Registry was conducted as a nationwide prospective observational study to investigate the present status of anticoagulation therapy and optimal anticoagulation therapy in Japanese patients with AF.[21](#jah31743-bib-0021){ref-type="ref"} The study design and baseline patient characteristics have been reported elsewhere.[3](#jah31743-bib-0003){ref-type="ref"}, [21](#jah31743-bib-0021){ref-type="ref"} Briefly, the study protocol conformed to the Declaration of Helsinki and was approved by the ethics committee of each participating institution. All participants gave written informed consent at the time of enrollment. A consecutive series of outpatients with AF of any type was enrolled from 158 institutions, regardless of the use of antithrombotic drugs. All drugs, including antihypertensive drugs, and their dosages were selected at the discretion of the treating cardiologists. Patients with valvular AF[22](#jah31743-bib-0022){ref-type="ref"} were excluded from this subanalysis. Seated brachial BP was measured in each patient at the time of enrollment (baseline) and at each follow‐up visit by either the auscultatory method or an automated sphygmomanometer, as was appropriate at each institution. Hypertension was defined as a peripheral systolic BP ≥140 mm Hg, a diastolic BP ≥90 mm Hg,[23](#jah31743-bib-0023){ref-type="ref"} a prior history of hypertension, and/or the use of antihypertensive drugs.[21](#jah31743-bib-0021){ref-type="ref"}

Follow‐Up and Definition of End Points {#jah31743-sec-0008}
--------------------------------------

Patients were followed up for 2 years or until an event, whichever occurred first. Thromboembolism included symptomatic ischemic stroke, transient ischemic attack, and systemic embolic events. Major hemorrhage included intracranial hemorrhage (ICH), gastrointestinal hemorrhage, and other hemorrhages requiring hospitalization. If any event occurred during the follow‐up period, BP values at the time prior to and closest to the event were obtained.[21](#jah31743-bib-0021){ref-type="ref"} The diagnostic criteria for each event have been described elsewhere.[3](#jah31743-bib-0003){ref-type="ref"}, [21](#jah31743-bib-0021){ref-type="ref"}

Grouping of Patients {#jah31743-sec-0009}
--------------------

Patients were divided into 2 groups based on the presence of hypertension at the time of enrollment (Hypertension and No‐hypertension) and event incidence rates between the 2 groups were compared. In addition, patients were divided into 4 groups according to the quartiles of their systolic BP at baseline (Q1, \<116; Q2, 116--125; Q3, 126--135; and Q4, ≥136 mm Hg) and at the time prior to and closest to an event or at the end of follow‐up (Q1, \<114; Q2, 114--125; Q3, 126--135; and Q4, ≥136 mm Hg). Patients were also divided into quartiles based on their diastolic BP.

Statistical Analysis {#jah31743-sec-0010}
--------------------

Data are presented as mean±SD. The statistical significance of differences in mean values was analyzed using Student *t* test or analysis of variance, as appropriate. Frequencies of parameters or events were compared using the χ^2^ test or Fisher\'s exact test, as appropriate. Trend among the quartiles was tested by Cochran‐Armitage test for categorical variables or Jonckheere‐Terpstra test for continuous variables, as appropriate. Kaplan--Meier curves between 2 groups were compared with log‐rank tests. A Cox proportional hazards model was used to investigate the influence of hypertension and baseline BP values on events. Odds ratios (ORs) of BP quartiles at the time closest to the event or at the end of the follow‐up period were calculated with multivariate logistic regression analysis. Explanatory variables for multivariate analysis were adopted from well‐known risk factors, i.e., unadjusted model (Model 1) and adjusted models for other components (except hypertension) of CHADS~2~ score (Model 2), other components (except hypertension) of CHA~2~DS~2~‐VASc score (Model 3), and Model 3 plus use of warfarin and antiplatelet (Model 4). The use of antihypertensive drugs was not included as an explanatory variable for multivariate analysis to avoid multicollinearity. Additionally, ORs of BP quartiles for major hemorrhage and ICH were determined after adjustment for other components (except hypertension) of HAS‐BLED score[18](#jah31743-bib-0018){ref-type="ref"} in 7015 patients with data available for the calculation of this score. In the present analysis, "H" in the HAS‐BLED score was defined as a systolic BP ≥140 mm Hg at the time of enrollment. "L" and "D" were defined as 1 or more episode(s) of INR ≥3.5 during the follow‐up period and concomitant antiplatelet use, respectively.[15](#jah31743-bib-0015){ref-type="ref"}, [18](#jah31743-bib-0018){ref-type="ref"} The optimal cutoff BP values for thromboembolic and hemorrhagic events were determined as the points closest to the top‐left corner of the receiver operating characteristic curves (minimum of \[1−sensitivity\]^2^+\[1−specificity\]^2^). Two‐tailed *P*‐values of \<0.05 were considered to be statistically significant. All statistical analyses were performed with SPSS software version 23.0 (IBM Corporation, Armonk, NY).

Results {#jah31743-sec-0011}
=======

Of 7937 patients with AF enrolled in the J‐RHYTHM Registry,[3](#jah31743-bib-0003){ref-type="ref"} 421 patients were excluded because they had valvular AF.[22](#jah31743-bib-0022){ref-type="ref"} Of the remaining 7516 patients with NVAF, 110 (1.5%) patients were lost to follow‐up. Therefore, a total of 7406 patients with NVAF were included in the present analyses.[16](#jah31743-bib-0016){ref-type="ref"}

Baseline Patient Characteristics and Medications {#jah31743-sec-0012}
------------------------------------------------

Baseline patient characteristics and medications of the 2 groups are shown in Table [1](#jah31743-tbl-0001){ref-type="table-wrap"}. Male sex, cardiomyopathy, and heart failure were less prevalent in the Hypertension group than in the No‐hypertension group. By contrast, mean age, CHADS~2~ score, and the prevalence of diabetes mellitus, use of warfarin or antiplatelet, coadministration of warfarin and antiplatelet, and use of antihypertensive drugs were all higher in the Hypertension group (Table [1](#jah31743-tbl-0001){ref-type="table-wrap"}). Mean INR and distribution of INR were comparable between the 2 groups, but time in therapeutic range [24](#jah31743-bib-0024){ref-type="ref"} was slightly, but significantly, better in the Hypertension group than in the No‐hypertension group (Table [1](#jah31743-tbl-0001){ref-type="table-wrap"}). Although 94.8% of patients were taking antihypertensive drugs, baseline BP was higher in the Hypertension group than in the No‐hypertension group (Table [1](#jah31743-tbl-0001){ref-type="table-wrap"}). Patient characteristics and medications in the quartiles of systolic BP at the time of enrollment are summarized in Table [2](#jah31743-tbl-0002){ref-type="table-wrap"}. The prevalence of hypertension was 41.2%, 43.1%, 64.8%, and 78.7% in quartiles 1 to 4, respectively (Table [2](#jah31743-tbl-0002){ref-type="table-wrap"}). Significant trends among quartiles were observed for baseline frequencies of several comorbidities and medications (Table [2](#jah31743-tbl-0002){ref-type="table-wrap"}).

###### 

Baseline Patient Characteristics and Medications

                                                  Overall       No‐Hypertension   Hypertension   *P‐*Value[a](#jah31743-note-0004){ref-type="fn"}
  ----------------------------------------------- ------------- ----------------- -------------- --------------------------------------------------
  Number of patients                              7406          2929              4477           
  Age, y                                          69.8±10.0     68.1±10.8         70.8±9.2       \<0.001
  Sex, male                                       5241 (70.8)   2146 (73.3)       3095 (69.1)    \<0.001
  Type of AF                                                                                     
  Paroxysmal                                      2835 (38.3)   1123 (38.3)       1712 (38.2)    \<0.001
  Persistent                                      1081 (14.6)   459 (15.7)        622 (13.9)     
  Permanent                                       3490 (47.1)   1347 (46.0)       2143 (47.9)    
  Comorbidities                                                                                  
  Coronary artery disease                         781 (10.5)    261 (8.9)         520 (11.6)     0.115
  Cardiomyopathy                                  634 (8.6)     348 (11.9)        286 (6.4)      \<0.001
  HCM                                             264 (3.6)     115 (3.9)         149 (3.6)      0.196
  DCM                                             370 (5.0)     233 (8.0)         137 (3.3)      \<0.001
  Congenital heart disease                        96 (1.3)      56 (1.9)          40 (0.9)       0.133
  COPD                                            131 (1.8)     53 (1.8)          78 (1.7)       0.901
  Hyperthyroidism                                 131 (1.8)     61 (2.1)          70 (1.6)       0.419
  Risk factors for stroke                                                                        
  Heart failure                                   2055 (27.7)   850 (29.0)        1205 (26.9)    \<0.001
  Hypertension                                    4477 (60.5)   0 (0.0)           4477 (100.0)   \<0.001
  Age (≥75 y)                                     2565 (34.6)   880 (30.0)        1685 (37.6)    0.002
  Diabetes mellitus                               1359 (18.3)   427 (14.6)        932 (20.8)     0.002
  Stroke/TIA                                      1022 (13.8)   380 (13.0)        642 (14.3)     0.103
  CHADS~2~ score                                                                                 
  0                                               1157 (15.6)   1157 (39.5)       0 (0.0)        \<0.001
  1                                               2512 (33.9)   967 (33.0)        1545 (34.5)    
  ≥2                                              3737 (50.5)   805 (27.5)        2932 (65.5)    
  Mean                                            1.7±1.2       1.0±1.0           2.1±1.1        \<0.001
  CHA~2~DS~2~‐VASc score                                                                         
  0                                               487 (6.6)     487 (16.6)        0 (0.0)        \<0.001
  1                                               1147 (15.5)   671 (22.9)        476 (10.6)     
  2                                               1666 (22.5)   758 (25.9)        908 (20.3)     
  ≥3                                              4106 (55.4)   1013 (34.6)       3093 (69.1)    
  Mean                                            2.8±1.6       2.0±1.4           3.3±1.5        \<0.001
  HAS‐BLED score, \[n\]                           \[7015\]      \[2766\]          \[4249\]       
  0                                               1117 (15.9)   603 (21.8)        514 (12.1)     \<0.001
  1                                               2689 (38.3)   1183 (42.8)       1506 (35.4)    
  2                                               2140 (30.5)   719 (26.0)        1421 (33.4)    
  ≥3                                              1069 (15.2)   261 (9.4)         808 (19.0)     
  Mean                                            1.5±1.0       1.3±0.9           1.6±1.0        \<0.001
  Systolic BP, mm Hg                              126.0±16.2    120.1±14.8        129.8±15.9     \<0.001
  Diastolic BP, mm Hg                             73.5±17.0     71.1±10.5         75.1±19.9      \<0.001
  Heart rate/min                                  72.5±13.2     72.8±12.9         72.3±13.4      0.111
  Medications                                                                                    
  Warfarin                                        6404 (86.5)   2461 (84.0)       3943 (88.1)    \<0.001
  Dosage, mg/day                                  2.9±1.2       2.9±1.2           2.8±1.1        \<0.001
  INR                                                                                            
  \<1.6                                           1670 (26.1)   674 (27.4)        996 (25.3)     0.366
  1.6 to 1.99                                     2348 (36.7)   879 (35.7)        1469 (37.3)    
  2.0 to 2.59                                     1854 (29.0)   704 (28.6)        1150 (29.2)    
  2.6 to 2.99                                     363 (5.7)     143 (5.8)         220 (5.6)      
  ≥3.0                                            169 (2.6)     61 (2.5)          108 (2.7)      
  Mean                                            1.91±0.49     1.90±0.51         1.91±0.48      0.427
  TTR[b](#jah31743-note-0005){ref-type="fn"}, %   59.3±29.2     56.9±29.8         60.8±28.7      \<0.001
                                                  \[n=6064\]    \[n=2330\]        \[n=3734\]     
  Antiplatelet                                    1937 (26.2)   659 (22.5)        1278 (28.5)    \<0.001
  Aspirin                                         1675 (22.6)   580 (19.8)        1095 (24.5)    \<0.001
  Others                                          433 (5.8)     129 (4.4)         304 (6.8)      \<0.001
  Warfarin+antiplatelet                           1358 (18.3)   417 (14.2)        941 (21.0)     \<0.001
  Antihypertensive drugs                          5354 (72.3)   1108 (37.8)       4246 (94.8)    \<0.001
  ARB/ACE‐I                                       3934 (53.1)   655 (22.4)        3279 (73.2)    \<0.001
  Others                                          3545 (47.9)   716 (24.4)        2829 (63.2)    \<0.001

Data are number of patients (%) or mean±SD. ACE‐I indicates angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BP, blood pressure; CHADS~2~, congestive heart failure, hypertension, age ≥75 y, diabetes mellitus, and history of stroke or TIA; CHA~2~DS~2~‐VASc, additionally, vascular disease (coronary artery disease), age 65 to 74 y, and female sex; COPD, chronic obstructive pulmonary disease; DCM, dilated cardiomyopathy; HAS‐BLED, hypertension (systolic BP ≥140 mm Hg), abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR (episodes of INR ≥3.5), elderly (age \>65 y), drugs (use of antiplatelets)/alcohol concomitantly; HCM, hypertrophic cardiomyopathy; INR, international normalized ratio of prothrombin time; TIA, transient ischemic attack; TTR, time in therapeutic range.

Comparison between 2 groups with and without hypertension.

Target INR was 2.0 to 3.0 (\<70 y) or 1.6 to 2.6 (≥70 y).

###### 

Baseline Patient Characteristics and Medications of Each Quartile

                                                  Quartile 1    Quartile 2    Quartile 3    Quartile 4    *P‐*Value for Trend
  ----------------------------------------------- ------------- ------------- ------------- ------------- ---------------------
  Number of patients                              1844          1820          1765          1977          
  Age, y                                          68.9±10.6     68.5±10.3     69.8±9.8      70.8±9.1      \<0.001
  Sex, male                                       1365 (74.0)   1301 (71.5)   1237 (70.1)   1338 (67.7)   \<0.001
  Type of AF                                                                                              
  Paroxysmal                                      616 (33.4)    713 (39.2)    705 (39.9)    801 (40.5)    \<0.001
  Persistent                                      286 (15.5)    268 (14.7)    264 (15.0)    263 (13.3)    
  Permanent                                       942 (51.1)    839 (46.1)    796 (45.1)    913 (46.2)    
  Comorbidities                                                                                           
  Coronary artery disease                         197 (10.7)    198 (10.9)    204 (11.6)    182 (9.2)     0.208
  Cardiomyopathy                                  253 (13.7)    154 (8.5)     116 (6.6)     111 (5.6)     \<0.001
  HCM                                             84 (4.6)      63 (3.5)      58 (3.3)      59 (3.0)      0.011
  DCM                                             169 (9.2)     91 (5.0)      58 (3.3)      52 (2.6)      \<0.001
  Congenital heart disease                        37 (2.0)      19 (1.0)      13 (0.7)      23 (1.2)      0.015
  COPD                                            46 (2.5)      21 (1.2)      31 (1.8)      33 (1.7)      0.172
  Hyperthyroidism                                 40 (2.2)      31 (1.7)      29 (1.6)      31 (1.6)      0.172
  Risk factors for stroke                                                                                 
  Heart failure                                   683 (37.0)    495 (27.2)    445 (25.2)    432 (21.9)    \<0.001
  Hypertension                                    759 (41.2)    785 (43.1)    1144 (64.8)   1556 (78.7)   \<0.001
  Age (≥75 y)                                     587 (31.8)    630 (34.6)    603 (34.2)    745 (37.7)    \<0.001
  Diabetes mellitus                               291 (15.8)    324 (17.8)    357 (20.2)    387 (19.6)    \<0.001
  Stroke/TIA                                      262 (14.2)    250 (13.7)    253 (14.3)    257 (13.0)    0.376
  CHADS~2~ score                                                                                          
  0                                               389 (21.1)    344 (18.9)    247 (14.0)    177 (9.0)     0.135
  1                                               609 (33.0)    586 (32.2)    621 (35.2)    696 (35.2)    
  ≥2                                              846 (45.9)    890 (48.9)    897 (50.8)    1104 (55.8)   
  Mean                                            1.5±1.2       1.6±1.3       1.7±1.2       1.8±1.2       0.367
  CHA~2~DS~2~‐VASc score                                                                                  
  0                                               170 (9.2)     148 (8.1)     106 (6.0)     63 (3.2)      \<0.001
  1                                               329 (17.8)    293 (16.1)    269 (15.2)    256 (12.9)    
  2                                               437 (23.7)    409 (22.5)    384 (21.8)    436 (22.1)    
  ≥3                                              908 (49.2)    970 (53.3)    1006 (57.0)   1222 (61.8)   
  Mean                                            2.6±1.6       2.7±1.6       2.9±1.6       3.0±1.5       \<0.001
  HAS‐BLED score \[n\]                            \[1764\]      \[1708\]      \[1664\]      \[1879\]      
  0                                               360 (20.4)    360 (21.1)    311 (18.7)    86 (4.6)      \<0.001
  1                                               794 (45.0)    738 (43.2)    734 (44.1)    423 (22.5)    
  2                                               457 (25.9)    441 (25.8)    465 (27.9)    777 (23.3)    
  ≥3                                              153 (8.7)     169 (9.9)     154 (9.3)     593 (31.6)    
  Mean                                            1.2±0.9       1.3±0.9       1.3±0.9       2.1±1.0       \<0.001
  Systolic BP, mm Hg                              105.8±7.2     120.7±2.6     130.1±2.7     146.0±9.7     \<0.001
  Diastolic BP, mm Hg                             65.2±19.4     71.5±9.0      76.4±21.3     80.6±11.1     \<0.001
  Heart rate/min                                  72.3±13.1     72.4±13.4     72.1±12.7     73.0±13.5     0.127
  Medications                                                                                             
  Warfarin                                        1624 (88.1)   1562 (85.8)   1517 (85.9)   1701 (86.0)   0.094
  Dosage, mg/day                                  2.8±1.2       2.9±1.2       2.9±1.2       2.9±1.2       0.004
  INR                                                                                                     
  \<1.6                                           397 (24.4)    401 (25.7)    394 (26.0)    478 (28.1)    0.002
  1.6 to 1.99                                     589 (36.3)    571 (36.6)    544 (35.9)    644 (37.9)    
  2.0 to 2.59                                     487 (30.0)    478 (30.6)    441 (29.1)    448 (26.3)    
  2.6 to 2.99                                     111 (6.8)     74 (4.7)      92 (6.1)      86 (5.1)      
  ≥3.0                                            40 (2.5)      38 (2.4)      46 (3.0)      45 (2.6)      
  Mean                                            1.89±0.52     1.91±0.48     1.91±0.49     1.88±0.49     0.001
  TTR[a](#jah31743-note-0007){ref-type="fn"}, %   58.3±28.7     59.0±29.5     60.2±29.5     59.9±29.1     0.042
                                                  \[n=1544\]    \[n=1488\]    \[n=1439\]    \[n=1593\]    
  Antiplatelet                                    432 (23.4)    485 (26.6)    472 (26.7)    548 (27.7)    0.004
  Aspirin                                         376 (20.9)    431 (23.7)    409 (23.2)    449 (22.7)    0.273
  Others                                          76 (4.1)      106 (5.8)     118 (6.7)     138 (7.0)     \<0.001
  Warfarin+antiplatelet                           297 (16.1)    298 (16.4)    331 (18.8)    385 (19.5)    0.001
  Antihypertensive drugs                          1239 (67.2)   1237 (68.0)   1303 (73.8)   1575 (79.7)   \<0.001
  ARB/ACE‐I                                       867 (47.0)    882 (48.5)    958 (54.3)    1227 (62.1)   \<0.001
  Others                                          819 (44.4)    544 (46.4)    866 (49.1)    1016 (51.4)   \<0.001

Data are number of patients (%) or mean±SD. ACE‐I indicates angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BP, blood pressure; CHADS~2~, congestive heart failure, hypertension, age ≥75 y, diabetes mellitus, and history of stroke or TIA; CHA~2~DS~2~‐VASc, additionally, vascular disease (coronary artery disease), age 65 to 74 y, and female sex; COPD, chronic obstructive pulmonary disease; DCM, dilated cardiomyopathy; HAS‐BLED, hypertension (systolic BP ≥140 mm Hg), abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR (episodes of INR ≥3.5), elderly (age \>65 y), drugs (use of antiplatelets)/alcohol concomitantly; HCM, hypertrophic cardiomyopathy; INR, international normalized ratio of prothrombin time; TIA, transient ischemic attack; TTR, time in therapeutic range.

Target INR was 2.0 to 3.0 (\<70 y) or 1.6 to 2.6 (≥70 y).

Event Rates and Hypertension {#jah31743-sec-0013}
----------------------------

During the 2‐year follow‐up period, thromboembolic events occurred in 126 patients (1.7%) and major hemorrhagic events occurred in 140 patients (1.9%), including ICH in 50 patients (0.7%). The unadjusted 2‐year incidence rate of thromboembolism was similar between the 2 groups (1.8% in the Hypertension group versus 1.6% in the No‐hypertension group, *P*=0.540), whereas the rate of major hemorrhage was higher in the Hypertension group than in the No‐hypertension group (2.3% versus 1.3%, *P*=0.006) (Table [3](#jah31743-tbl-0003){ref-type="table-wrap"}). The Kaplan--Meier curves for thromboembolism and major hemorrhage are shown in Figure [1](#jah31743-fig-0001){ref-type="fig"}. There was no significant difference in the event‐free rate of thromboembolism between the 2 groups (*P*=0.478 by log‐rank test) (Figure [1](#jah31743-fig-0001){ref-type="fig"}A), whereas event‐free rate of major hemorrhage was significantly lower in the Hypertension group than in the No‐hypertension group (*P*=0.004 by log‐rank test) (Figure [1](#jah31743-fig-0001){ref-type="fig"}B). The hazard ratio (HR) of hypertension for thromboembolism was not significantly high in any model (Table [4](#jah31743-tbl-0004){ref-type="table-wrap"}). By contrast, the HRs of hypertension for major hemorrhage were significantly high in the crude model (Model 1) and in all adjusted models (Models 2, 3, and 4) (Table [4](#jah31743-tbl-0004){ref-type="table-wrap"}).

###### 

Two‐Year Incidence Rates of Events

  Presence of Hypertension   No‐Hypertension   Hypertension   *P‐*Value[a](#jah31743-note-0009){ref-type="fn"}
  -------------------------- ----------------- -------------- --------------------------------------------------
  Number of patients         2929              4477           
  Thromboembolism            46 (1.6%)         80 (1.8%)      0.540
  Cerebral infarction        38                66             
  TIA                        4                 5              
  Systemic embolism          4                 9              
  Major hemorrhage           39 (1.3%)         101 (2.3%)     0.006
  Intracranial               12                38             
  Gastrointestinal           10                37             
  Others                     17                26             

  Quartiles of SBP at the Time of Enrollment, mm Hg   Quartile 1 (\<116)   Quartile 2 (116--125)   Quartile 3 (126--135)   Quartile 4 (≥136)   *P‐*Value for Trend
  --------------------------------------------------- -------------------- ----------------------- ----------------------- ------------------- ---------------------
  Number of patients                                  1844                 1820                    1765                    1977                
  Thromboembolism                                     32 (1.7%)            32 (1.8%)               27 (1.5%)               35 (1.8%)           0.941
  Cerebral infarction                                 23                   26                      26                      29                  
  TIA                                                 5                    3                       0                       1                   
  Systemic embolism                                   4                    3                       1                       5                   
  Major hemorrhage                                    32 (1.7%)            30 (1.6%)               33 (1.9%)               45 (2.3%)           0.181
  Intracranial                                        13                   13                      9                       15                  
  Gastrointestinal                                    10                   7                       16                      14                  
  Others                                              9                    10                      8                       16                  

  Quartiles of SBP at the Time Closest to Event, mm Hg        Quartile 1 (\<114)   Quartile 2 (114--125)   Quartile 3 (126--135)   Quartile 4 (≥136)   *P‐*Value for Trend
  ----------------------------------------------------------- -------------------- ----------------------- ----------------------- ------------------- ---------------------
  Number of patients[b](#jah31743-note-0010){ref-type="fn"}   1680                 1869                    1711                    1843                
  Thromboembolism                                             22 (1.3%)            17 (0.9%)               12 (0.7%)               66 (3.6%)           \<0.001
  Cerebral infarction                                         16                   14                      7                       60                  
  TIA                                                         4                    1                       2                       1                   
  Systemic embolism                                           2                    2                       3                       5                   
  Major hemorrhage                                            32 (1.9%)            25 (1.3%)               23 (1.3%)               52 (2.8%)           0.041
  Intracranial                                                6                    4                       10                      29                  
  Gastrointestinal                                            15                   9                       9                       11                  
  Others                                                      11                   12                      4                       12                  

Data are number of patients (%). SBP indicates systolic blood pressure; TIA, transient ischemic attack.

Comparison between 2 groups.

No blood pressure data at the time closest to event or at the end of follow‐up in 303 patients.

![Kaplan--Meier curves of thromboembolism (A) and major hemorrhage (B). Additional boxes show the magnified event‐free curves with 10‐fold scale. *P*‐values: comparison between No‐hypertension and Hypertension groups by log‐rank test.](JAH3-5-e004075-g001){#jah31743-fig-0001}

###### 

Influence of Hypertension on Thromboembolism and Major Hemorrhage (Cox Proportional Hazards Model)

                            Model 1             Model 2   Model 3             Model 4                                                     
  ------------------------- ------------------- --------- ------------------- --------- ------------------- --------- ------------------- ---------
  *Thromboembolism*                                                                                                                       
  Hypertension              1.14 (0.79--1.64)   0.479     1.03 (0.72--1.49)   0.862     1.03 (0.72--1.49)   0.864     1.05 (0.73--1.52)   0.787
  Heart failure             ---                 ---       1.02 (0.70--1.50)   0.914     1.03 (0.70--1.52)   0.878     1.10 (0.75--1.63)   0.621
  Age (≥75 y)               ---                 ---       2.28 (1.60--3.29)   \<0.001   2.69 (1.63--4.45)   \<0.001   2.80 (1.69--4.64)   \<0.001
  Diabetes mellitus         ---                 ---       1.27 (0.83--1.94)   0.271     1.25 (0.81--1.91)   0.313     1.27 (0.83--1.95)   0.275
  Stroke/TIA                ---                 ---       1.75 (1.16--2.66)   0.008     1.72 (1.13--2.61)   0.011     1.82 (1.19--2.79)   0.006
  Coronary artery disease   ---                 ---       ---                 ---       0.96 (0.55--1.67)   0.889     0.92 (0.52--1.63)   0.771
  Age (65--74 y)            ---                 ---       ---                 ---       1.24 (0.72--2.14)   0.435     1.31 (0.76--2.26)   0.329
  Sex, female               ---                 ---       ---                 ---       0.78 (0.52--1.17)   0.228     0.77 (0.52--1.16)   0.210
  Warfarin use              ---                 ---       ---                 ---       ---                 ---       0.44 (0.28--0.68)   \<0.001
  Antiplatelet use          ---                 ---       ---                 ---       ---                 ---       1.08 (0.71--1.64)   0.720
  *Major hemorrhage*                                                                                                                      
  Hypertension              1.70 (1.17--2.46)   0.005     1.58 (1.09--2.30)   0.015     1.56 (1.08--2.27)   0.019     1.52 (1.05--2.21)   0.027
  Heart failure             ---                 ---       1.68 (1.20--2.37)   0.003     1.66 (1.18--2.32)   0.004     1.60 (1.14--2.26)   0.007
  Age (≥75 y)               ---                 ---       1.88 (1.34--2.63)   \<0.001   2.61 (1.59--4.29)   \<0.001   2.52 (1.53--4.14)   \<0.001
  Diabetes mellitus         ---                 ---       1.26 (0.85--1.86)   0.256     1.17 (0.79--1.74)   0.441     1.14 (0.76--1.70)   0.525
  Stroke/TIA                ---                 ---       1.67 (1.12--2.49)   0.012     1.58 (1.06--2.37)   0.025     1.49 (0.99--2.23)   0.055
  Coronary artery disease   ---                 ---       ---                 ---       1.31 (0.83--2.06)   0.240     1.16 (0.71--1.90)   0.556
  Age (65--74 y)            ---                 ---       ---                 ---       1.52 (0.90--2.55)   0.116     1.46 (0.87--2.46)   0.154
  Sex, female               ---                 ---       ---                 ---       0.60 (0.40--0.90)   0.013     0.61 (0.40--0.91)   0.016
  Warfarin use              ---                 ---       ---                 ---       ---                 ---       2.31 (1.11--4.82)   0.025
  Antiplatelet use          ---                 ---       ---                 ---       ---                 ---       1.32 (0.89--1.96)   0.167

Model 1: Unadjusted (crude); Model 2: Adjusted for other components of CHADS~2~ score (congestive heart failure, age ≥75 y, diabetes mellitus, and history of stroke or TIA); Model 3: Adjusted for other components of CHA~2~DS~2~‐VASc score (additionally, vascular disease \[coronary artery disease\], age 65--74 y, and female sex); Model 4: Adjusted for other components of CHA~2~DS~2~‐VASc score, warfarin use, and antiplatelet use. HR indicates hazard ratio; TIA, transient ischemic attack.

Event Rates and BP at the Time of Enrollment {#jah31743-sec-0014}
--------------------------------------------

Systolic BP at the time of enrollment in patients who were subsequently complicated with thromboembolism or major hemorrhage (127±20 or 128±17 mm Hg) was not different from that in event‐free patients (126±16 mm Hg). Diastolic BP at the time of enrollment in patients complicated with these events during the follow‐up period (74±13 and 73±11 mm Hg) was also similar to that in event‐free patients (74±17 mm Hg).

When patients were divided into quartiles of systolic BP at the time of enrollment, HRs for thromboembolism or major hemorrhage did not differ among the quartiles in any model; this was also true for quartiles of diastolic BP at the time of enrollment (Table [5](#jah31743-tbl-0005){ref-type="table-wrap"}). When baseline BP values were used as a continuous variable, adjusted risk (by Model 4) of thromboembolism and major hemorrhage tended to increase slightly for every 10‐mm Hg increase in baseline systolic BP (HR 1.02, 95% CI 0.92--1.14, *P*=0.724 for thromboembolism and HR 1.09, 95% CI 0.98--1.21, *P*=0.098 for major hemorrhage), although not statistically significant either.

###### 

Influence of Blood Pressure at the Time of Enrollment

                                Model 1             Model 2   Model 3             Model 4                                                   
  ----------------------------- ------------------- --------- ------------------- --------- ------------------- ------- ------------------- -------
  Thromboembolism                                                                                                                           
  Systolic BP                                                                                                                               
  Quartile 1 (\<116 mm Hg)      1.00 (reference)              1.00 (reference)              1.00 (reference)            1.00 (reference)    
  Quartile 2 (116--125 mm Hg)   1.00 (0.61--1.64)   0.990     0.97 (0.59--1.59)   0.905     0.98 (0.60--1.60)   0.922   0.96 (0.59--1.58)   0.881
  Quartile 3 (126--135 mm Hg)   0.86 (0.52--1.44)   0.565     0.83 (0.49--1.38)   0.465     0.83 (0.50--1.39)   0.480   0.84 (0.50--1.41)   0.417
  Quartile 4 (≥136 mm Hg)       1.01 (0.63--1.63)   0.968     0.96 (0.59--1.55)   0.853     0.96 (0.59--1.57)   0.878   0.86 (0.59--1.57)   0.801
  Diastolic BP                                                                                                                              
  Quartile 1 (\<66 mm Hg)       1.00 (reference)              1.00 (reference)              1.00 (reference)            1.00 (reference)    
  Quartile 2 (66--72 mm Hg)     1.04 (0.63--1.70)   0.885     1.11 (0.68--1.83)   0.668     1.12 (0.68--1.83)   0.657   1.11 (0.68--1.82)   0.681
  Quartile 3 (73--79 mm Hg)     0.96 (0.55--1.68)   0.875     1.08 (0.61--1.90)   0.795     1.09 (0.62--1.91)   0.774   1.07 (0.61--1.88)   0.821
  Quartile 4 (≥80 mm Hg)        0.96 (0.60--1.55)   0.870     1.15 (0.71--1.87)   0.551     1.16 (0.72--1.88)   0.545   1.16 (0.71--1.88)   0.559
  Major hemorrhage                                                                                                                          
  Systolic BP                                                                                                                               
  Quartile 1 (\<116 mm Hg)      1.00 (reference)              1.00 (reference)              1.00 (reference)            1.00 (reference)    
  Quartile 2 (116--125 mm Hg)   0.94 (0.57--1.55)   0.810     0.97 (0.59--1.59)   0.893     0.97 (0.59--1.61)   0.915   0.97 (0.59--1.60)   0.905
  Quartile 3 (126--135 mm Hg)   1.05 (0.65--1.71)   0.836     1.09 (0.67--1.77)   0.741     1.09 (0.67--1.78)   0.726   1.10 (0.67--1.80)   0.702
  Quartile 4 (≥136 mm Hg)       1.30 (0.83--2.05)   0.256     1.36 (0.86--2.15)   0.192     1.38 (0.87--2.19)   0.167   1.37 (0.87--2.18)   0.175
  Diastolic BP                                                                                                                              
  Quartile 1 (\<65 mm Hg)       1.00 (reference)              1.00 (reference)              1.00 (reference)            1.00 (reference)    
  Quartile 2 (66--72 mm Hg)     1.33 (0.84--2.13)   0.227     1.48 (0.92--2.36)   0.103     1.50 (0.94--2.39)   0.091   1.50 (0.94--2.40)   0.089
  Quartile 3 (73--79 mm Hg)     0.87 (0.49--1.54)   0.626     1.03 (0.58--1.84)   0.926     1.05 (0.59--1.88)   0.869   1.06 (0.59--1.89)   0.857
  Quartile 4 (≥80 mm Hg)        1.10 (0.69--1.75)   0.680     1.39 (0.87--2.23)   0.167     1.43 (0.89--2.28)   0.140   1.42 (0.88--2.27)   0.148

Model 1: Unadjusted (crude); Model 2: Adjusted for other components of CHADS~2~ score (congestive heart failure, age ≥75 y, diabetes mellitus, and history of stroke or TIA); Model 3: Adjusted for other components of CHA~2~DS~2~‐VASc score (additionally, vascular disease \[coronary artery disease\], age 65--74 y, and female sex); Model 4: Adjusted for other components of CHA~2~DS~2~‐VASc score, warfarin use, and antiplatelet use. BP indicates blood pressure; HR, hazard ratio; TIA, transient ischemic attack.

Event Rates and BP at the Time Closest to the Event {#jah31743-sec-0015}
---------------------------------------------------

Systolic BP at the time prior to and closest to the event (mean, 10 days) in patients who were complicated with thromboembolism or major hemorrhage (140±29 or 132±30 mm Hg, respectively) was significantly higher than that at the end of follow‐up in event‐free patients (126±17 mm Hg, *P*\<0.001 for each). Diastolic BP was significantly higher in patients with thromboembolism (78±15 mm Hg) than in event‐free patients (73±11 mm Hg, *P*\<0.001), but did not differ between patients with major hemorrhage (75±17 mm Hg) and event‐free patients (*P*=0.108).

When patients were divided into quartiles of systolic BP at the time closest to the event or at the end of follow‐up, the rate of thromboembolism was significantly lower and that of major hemorrhage was significantly higher in patients receiving warfarin of the highest quartile (Q4) (Figure [2](#jah31743-fig-0002){ref-type="fig"}). The ORs for thromboembolism in Q4 of systolic BP were significantly higher than those in the lowest quartile (Q1) in all models (Models 1--4); this was also true for quartiles of diastolic BP (Table [6](#jah31743-tbl-0006){ref-type="table-wrap"}). The OR for major hemorrhage in Q4 of systolic BP was also significantly higher than that in Q1 in adjusted models (Models 2, 3, and 4) (Table [6](#jah31743-tbl-0006){ref-type="table-wrap"}). No significant difference in adjusted OR for major hemorrhage was observed for diastolic BP (Table [6](#jah31743-tbl-0006){ref-type="table-wrap"}).

![Two‐year incidence of thromboembolism (A) and major hemorrhage (B) in each quartile of blood pressure. *P*‐values: comparison between patients with and without warfarin in each quartile of blood pressure. BP, blood pressure at the time closest to the event or at the end of follow‐up.](JAH3-5-e004075-g002){#jah31743-fig-0002}

###### 

Influence of Blood Pressure at the Time Closest to the Event or at the End of Follow‐Up

                                Model 1             Model 2   Model 3             Model 4                                                     
  ----------------------------- ------------------- --------- ------------------- --------- ------------------- --------- ------------------- ---------
  Thromboembolism                                                                                                                             
  Systolic BP                                                                                                                                 
  Quartile 1 (\<114 mm Hg)      1.00 (reference)              1.00 (reference)              1.00 (reference)              1.00 (reference)    
  Quartile 2 (114--125 mm Hg)   0.69 (0.37--1.31)   0.257     0.72 (0.38--1.37)   0.319     0.72 (0.38--1.37)   0.315     0.75 (0.40--1.43)   0.384
  Quartile 3 (126--135 mm Hg)   0.53 (0.26--1.08)   0.081     0.56 (0.27--1.14)   0.108     0.55 (0.27--1.13)   0.103     0.56 (0.28--1.15)   0.113
  Quartile 4 (≥136 mm Hg)       2.80 (1.72--4.56)   \<0.001   2.87 (1.75--4.70)   \<0.001   2.86 (1.74--4.69)   \<0.001   2.88 (1.75--4.74)   \<0.001
  Diastolic BP                                                                                                                                
  Quartile 1 (\<65 mm Hg)       1.00 (reference)              1.00 (reference)              1.00 (reference)              1.00 (reference)    
  Quartile 2 (65--71 mm Hg)     0.66 (0.36--1.20)   0.175     0.75 (0.41--1.37)   0.348     0.75 (0.41--1.37)   0.342     0.76 (0.42--1.42)   0.411
  Quartile 3 (72--79 mm Hg)     0.70 (0.38--1.29)   0.252     0.84 (0.46--1.56)   0.589     0.84 (0.46--1.56)   0.588     0.86 (0.46--1.60)   0.638
  Quartile 4 (≥80 mm Hg)        1.65 (1.01--2.56)   0.046     2.04 (1.27--3.29)   0.003     2.05 (1.27--3.31)   0.003     2.09 (1.29--3.38)   0.003
  Major hemorrhage                                                                                                                            
  Systolic BP                                                                                                                                 
  Quartile 1 (\<114 mm Hg)      1.00 (reference)              1.00 (reference)              1.00 (reference)              1.00 (reference)    
  Quartile 2 (114--125 mm Hg)   0.70 (0.41--1.18)   0.182     0.76 (0.45--1.29)   0.304     0.75 (0.44--1.28)   0.291     0.74 (0.43--1.26)   0.262
  Quartile 3 (126--135 mm Hg)   0.70 (0.41--1.20)   0.199     0.77 (0.44--1.32)   0.336     0.76 (0.44--1.31)   0.325     0.75 (0.44--1.30)   0.307
  Quartile 4 (≥136 mm Hg)       1.50 (0.96--2.33)   0.077     1.62 (1.03--2.54)   0.038     1.62 (1.03--2.56)   0.036     1.61 (1.02--2.53)   0.041
  Diastolic BP                                                                                                                                
  Quartile 1 (\<65 mm Hg)       1.00 (reference)              1.00 (reference)              1.00 (reference)              1.00 (reference)    
  Quartile 2 (65--71 mm Hg)     0.66 (0.36--1.20)   0.175     1.00 (0.61--1.64)   0.989     1.00 (0.61--1.63)   0.990     0.97 (0.60--1.59)   0.916
  Quartile 3 (72--79 mm Hg)     0.70 (0.38--1.29)   0.252     0.95 (0.57--1.61)   0.861     0.96 (0.57--1.62)   0.879     0.95 (0.56--1.61)   0.851
  Quartile 4 (≥80 mm Hg)        1.61 (1.01--2.56)   0.046     1.10 (0.69--1.77)   0.681     1.11 (0.69--1.78)   0.660     1.10 (0.68--1.76)   0.707

Model 1: Unadjusted (crude); Model 2: Adjusted for other components of CHADS~2~ score (congestive heart failure, age ≥75 y, diabetes mellitus, and history of stroke or TIA); Model 3: Adjusted for other components of CHA~2~DS~2~‐VASc score (additionally, vascular disease \[coronary artery disease\], age 65--74 y, and female sex); Model 4: Adjusted for other components of CHA~2~DS~2~‐VASc score, warfarin use, and antiplatelet use. BP indicates blood pressure; OR, odds ratio; TIA, transient ischemic attack.

After adjustment for other components of HAS‐BLED score, the OR for major hemorrhage in Q4 of systolic BP tended to be higher than that in Q1 (OR 1.44, 95% CI 0.91--2.27, *P*=0.124). By contrast, the OR for ICH in Q4 was markedly higher than that in Q1 (OR 4.55, 95% CI 1.89--10.96, *P*=0.001) (Figure [3](#jah31743-fig-0003){ref-type="fig"}).

![Odds ratios for major hemorrhage (A) and intracranial hemorrhage (B) in each quartile of blood pressure. Odds ratios were adjusted for other components (except hypertension) of HAS‐BLED score. See text for details. BP, blood pressure at the time closest to the event or at the end of follow‐up.](JAH3-5-e004075-g003){#jah31743-fig-0003}

Cutoff BP Values for Events {#jah31743-sec-0016}
---------------------------

Areas under the curve of the receiver operating characteristic analysis for thromboembolism, major hemorrhage, and ICH were 0.663 (95% CI 0.60--0.73, *P*\<0.001), 0.556 (95% CI 0.50--0.62, *P*=0.027), and 0.708 (95% CI 0.63--0.79, *P*\<0.001), respectively. Cutoff BP values were determined to be 137/79 mm Hg (with a sensitivity of 55.6% and a specificity of 77.0% for systolic BP), 130/73 mm Hg (53.0% and 58.8%), and 138/78 mm Hg (57.7% and 77.6%), for thromboembolism, major hemorrhage, and ICH, respectively.

Discussion {#jah31743-sec-0017}
==========

Although our previous reports partially revealed the influence of hypertension on event incidence,[14](#jah31743-bib-0014){ref-type="ref"}, [15](#jah31743-bib-0015){ref-type="ref"}, [16](#jah31743-bib-0016){ref-type="ref"}, [17](#jah31743-bib-0017){ref-type="ref"}, [18](#jah31743-bib-0018){ref-type="ref"}, [19](#jah31743-bib-0019){ref-type="ref"}, [20](#jah31743-bib-0020){ref-type="ref"} we confirmed in the present study that hypertension was not an independent risk factor for thromboembolism but a risk for major hemorrhage mostly in anticoagulated patients. Second, BP values at baseline were not related to the incidence of thromboembolism or major hemorrhage. By contrast, patients in the highest quartile of systolic BP (≥136 mm Hg) at the time closest to an event were characterized as high risk, with significantly higher ORs for thromboembolism, major hemorrhage, and ICH, even after adjustment for multiple confounders. Third, both the efficacy of stroke prevention and the undesirable increase in hemorrhage with warfarin were evident in the highest quartile of systolic BP of ≥136 mm Hg. Fourth, the cutoff BP values for thromboembolism, major hemorrhage, and ICH were determined to be 137/79, 130/73, and 138/78 mm Hg, respectively.

Hypertension and Thromboembolism {#jah31743-sec-0018}
--------------------------------

Hypertension is a well‐known risk factor for stroke. In the INTERSTROKE study, a large‐scale case--control study from 22 countries, self‐reported history of hypertension was the strongest risk factor for stroke of all types (OR 2.64, 99% CI 2.26--3.08). History of hypertension also had the highest OR for ischemic stroke (OR 2.37, 99% CI 2.00--2.79) compared with any other risk factors except for AF.[25](#jah31743-bib-0025){ref-type="ref"} Increasing BP is also related to increasing stroke risk.[26](#jah31743-bib-0026){ref-type="ref"} The influence of BP values on the event rates in anticoagulated patients with AF was investigated in the combined data set of the Stroke Prevention using an ORal Thrombin Inhibitor in AF (SPORTIF) III and V trials.[27](#jah31743-bib-0027){ref-type="ref"} The HR of the highest quartile of systolic BP for stroke/systemic embolic events was 1.83 (95% CI 1.22--2.74), and the event rate for stroke/systemic embolic events increased markedly at a mean systolic BP of \>140 mm Hg.[27](#jah31743-bib-0027){ref-type="ref"} In previous reports in patients with NVAF who were not receiving anticoagulation therapy, hypertension was an independent risk factor for ischemic stroke,[13](#jah31743-bib-0013){ref-type="ref"} whereas it was not in patients treated with warfarin.[14](#jah31743-bib-0014){ref-type="ref"}, [15](#jah31743-bib-0015){ref-type="ref"} Since these analyses were performed post hoc on data from prospective clinical studies, patient characteristics varied among studies.[13](#jah31743-bib-0013){ref-type="ref"}, [14](#jah31743-bib-0014){ref-type="ref"}, [15](#jah31743-bib-0015){ref-type="ref"}, [27](#jah31743-bib-0027){ref-type="ref"} In addition, since the definition of hypertension in CHADS~2~ and CHA~2~DS~2~‐VASc scores included a history of hypertension and antihypertensive drug use, measured BP values were not considered. In the present study, neither hypertension (defined as above) nor the BP value at the time of enrollment was an independent risk factor for thromboembolism. By contrast, the highest quartile of systolic BP (≥136 mm Hg) at the time closest to the event was detected as a significant risk factor for thromboembolism. Since 94.8% of patients received antihypertensive drugs and the mean BP was controlled \<130 mm Hg at the time of enrollment, even in the Hypertension group, these results appear reasonable.[11](#jah31743-bib-0011){ref-type="ref"}, [12](#jah31743-bib-0012){ref-type="ref"}

Hypertension and Major Hemorrhage {#jah31743-sec-0019}
---------------------------------

Hypertension is a clear risk factor for hemorrhagic stroke in the general population.[28](#jah31743-bib-0028){ref-type="ref"} In the INTERSTROKE study, self‐reported history of hypertension was the strongest risk factor for hemorrhagic stroke (OR 3.80, 99% CI 2.96--4.78) compared with other risk factors.[25](#jah31743-bib-0025){ref-type="ref"} The effects of hypertension and BP control on event rates during antithrombotic therapy were investigated in the Bleeding with Antithrombotic Therapy (BAT) Study in Japan.[29](#jah31743-bib-0029){ref-type="ref"} An increase in BP levels during antithrombotic treatment was positively associated with the development of ICH, suggesting that adequate BP control was important for avoiding ICH.[29](#jah31743-bib-0029){ref-type="ref"} In addition, the optimal cutoff BP level to predict impending risk of ICH was determined to be ≥130/81 mm Hg.[29](#jah31743-bib-0029){ref-type="ref"} In 2 of our previous reports in patients with NVAF, hypertension was not an independent risk factor for major hemorrhage.[14](#jah31743-bib-0014){ref-type="ref"}, [15](#jah31743-bib-0015){ref-type="ref"} In the former study, which aimed to determine the impact of sex on prognosis in patients with NVAF,[14](#jah31743-bib-0014){ref-type="ref"} the adjusted OR of hypertension for major hemorrhage was comparably high to that in the present study (OR 1.48, 95% CI 0.93--2.36, *P*=0.100). However, it was not statistically significant when factors with *P*\<0.25 in the antecedent univariate analysis were included as explanatory variables in the multivariate analysis. Consequently, the adopted explanatory variables differed from those in the present study. In the latter study, which aimed to assess the significance of each risk factor comprising the HAS‐BLED score in NVAF patients treated with warfarin,[15](#jah31743-bib-0015){ref-type="ref"} the adjusted HR of hypertension for major hemorrhage was not significantly high (HR 1.15, 95% CI 0.73--1.74, *P*=0.54), when the definition of hypertension was a systolic BP ≥140 mm Hg at the time of enrollment. By contrast, hypertension was detected as a significant risk factor for major hemorrhage in the present study, even after adjustment for other components of CHA~2~DS~2~‐VASc score, warfarin use, and antiplatelet use (Table [4](#jah31743-tbl-0004){ref-type="table-wrap"}). Hypertension, when including a history of hypertension in the definition, may have a larger contribution to the incidence of hemorrhagic events than to thromboembolism. By contrast, BP value at the time of enrollment was not a significant risk factor for major hemorrhage; however, systolic BP value at the time prior to and closest to the event was an independent risk factor for both major hemorrhage and thromboembolism, even in multiple adjusted models (Table [4](#jah31743-tbl-0004){ref-type="table-wrap"}). BP values at the time closest to the event would be more important for predicting both events than BP values at the time of enrollment.

In addition, we assessed the ORs of BP quartiles for major hemorrhage and ICH after adjustment for other components of the HAS‐BLED score.[15](#jah31743-bib-0015){ref-type="ref"}, [18](#jah31743-bib-0018){ref-type="ref"} This score contains warfarin and antiplatelet use, both of which are included in Model 4 of the present study. Although the OR for major hemorrhage in the highest quartile of systolic BP was not significant, the OR for ICH in the highest quartile of systolic BP at the time closest to the event was markedly higher compared with that in the lowest quartile, even after adjustment for the component of HAS‐BLED score (Figure [3](#jah31743-fig-0003){ref-type="fig"}). A systolic BP of ≥136 mm Hg would be a strong risk factor for ICH.

Optimal Cutoff BP Values for Events {#jah31743-sec-0020}
-----------------------------------

The present study has provided the cutoff BP values to predict impending risk of events. The accuracy of the receiver operating characteristic curves for thromboembolism and major hemorrhage based on areas under the curve was fair; the cutoff systolic BP values for these events (137 and 130 mm Hg, respectively) in the present analyses were comparable to those in previous recommendations.[29](#jah31743-bib-0029){ref-type="ref"}, [30](#jah31743-bib-0030){ref-type="ref"} The cutoff systolic BP for ICH in patients with NVAF in the present study (138 mm Hg) was higher than that in the BAT study (130 mm Hg).[29](#jah31743-bib-0029){ref-type="ref"} Patients in the BAT study were taking oral antithrombotic agents for the secondary prevention of cardiovascular or cerebrovascular diseases, regardless of AF,[29](#jah31743-bib-0029){ref-type="ref"} and therefore would be at higher risk for ICH than those in the present study.

Limitations {#jah31743-sec-0021}
===========

The present study had several limitations. First, this study was a post hoc analysis of data from the J‐RHYTHM Registry[3](#jah31743-bib-0003){ref-type="ref"}, [16](#jah31743-bib-0016){ref-type="ref"} and was therefore hypothesis‐generating in nature. Second, the registry was established in only 158 selected institutions in Japan and most of the participating physicians specialized in cardiology and in the management of cardiac arrhythmias. Therefore, these results may not be generalizable to the overall Japanese population with NVAF. Third, the method of BP measurement was not standardized. BP values were obtained by the auscultatory method or an automated sphygmomanometer, as appropriate for daily clinical practice in each institution. Although visit‐to‐visit variability in BP is a known risk factor for stroke,[31](#jah31743-bib-0031){ref-type="ref"} it was not considered in the present analysis. Instead, BP values at the time of enrollment and the time prior to and closest to the event were selected for the analysis. Changes in antihypertensive drugs and dosages during the follow‐up period were not considered in the analysis. Fourth, the HAS‐BLED score was missing in 391 patients with NVAF; these patients were excluded from Figure [3](#jah31743-fig-0003){ref-type="fig"}. In these 391 patients, thromboembolism occurred in 6 and major hemorrhage occurred in 9 patients, but no ICH events were observed.

Conclusions {#jah31743-sec-0022}
===========

A systolic BP of ≥136 mm Hg at the time closest to the event was an independent risk for thromboembolism and major hemorrhage. BP control appeared to be more important than a history of hypertension and baseline BP values at preventing thromboembolism and major hemorrhage in patients with NVAF.

Appendix {#jah31743-sec-0023}
========

The following persons participated in the J‐RHYTHM Registry: Executive Committee: H. Inoue, K. Okumura, H. Atarashi, and T. Yamashita. Local Executive Committee: M. Sakurai, Y. Kawamura (Hokkaido); K. Okumura, I. Kubota (Tohoku); Y. Kaneko, K. Matsumoto (North Kanto); S. Ogawa, H. Atarashi, T. Yamashita (South Kanto); H. Inoue, Y. Aizawa (Hokuetsu); I. Kodama, E. Watanabe (Chubu); Y. Koretsune, Y. Okuyama (Kansai); A. Shimizu, O. Igawa (Chugoku); S. Bando, M. Fukatani (Shikoku); T. Saikawa, A. Chishaki (Kyushu). Statistical Advisor: H. Origasa. Participating Investigators: N. Kato, K. Kanda, J. Kato, H. Obata, M. Aoki, H. Honda (Hokkaido); Y. Konta, T. Hatayama, Y. Abe, K. Terata, T. Yagi, A. Ishida, T. Komatsu, H. Tachibana, H. Suzuki, Y. Kamiyama, T. Watanabe, M. Oguma, M. Itoh, O. Hirono, Y. Tsunoda, K. Ikeda, T. Kanaya, K. Sakurai, H. Sukekawa, S. Nakada (Tohoku); T. Itoh, S. Tange, M. Manita, M. Ohta, H. Eguma, R. Kato, Y. Endo, T. Ogino, M. Yamazaki, H. Kanki, M. Uchida, S. Miyanaga, K. Shibayama, N. Toratani, T. Kojima, M. Ichikawa, M. Saito, Y. Umeda, T. Sawanobori, H. Sohara, S. Okubo, T. Okubo, T. Tokunaga, O. Kuboyama, H. Ito, Y. Kitahara (North Kanto); K. Sagara, T. Satoh, E. Kodani, K. Sugi, Y. Kobayashi, Y. Higashi, T. Katoh, Y. Hirayama, N. Matsumoto, M. Takano, T. Ikeda, S. Yusu, S. Niwano, Y. Nakazato, Y. Kawano, M. Sumiyoshi, N. Hagiwara, K. Murasaki, H. Mitamura, S. Nakagawa, K. Okishige, K. Azegami, H. Aoyagi, K. Sugiyama, M. Nishizaki, N. Yamawake, I. Watanabe, K. Ohkubo, H. Sakurada, S. Fukamizu, M. Suzuki, W. Nagahori, T. Nakamura, Y. Murakawa, N. Hayami, K. Yoshioka, M. Amino, K. Hirao, A. Yagishita, K. Ajiki, K. Fujiu, Y. Imai, A. Yamashina, T. Ishiyama (South Kanto); M. Sakabe, K. Nishida, H. Asanoi, H. Ueno, J. D. Lee, Y. Mitsuke, H. Furushima, K. Ebe, M. Tagawa, M. Sato, M. Morikawa (Hokuetsu); K. Yamashiro, K. Takami, T. Ozawa, M. Watarai, M. Yamauchi, H. Kamiya, H. Hirayama, Y. Yoshida, T. Murohara, Y. Inden, H. Osanai, N. Ohte, T. Goto, I. Morishima, T. Yamamoto, E. Fujii, M. Senga, H. Hayashi, T. Urushida, Y. Takada, R. Kato, N. Tsuboi, T. Noda, T. Hirose, T. Onodera, S. Kageyama, T. Osaka, T. Tomita, K. Shimada, M. Nomura, H. Izawa, A. Sugiura, T. Arakawa, K. Kimura (Chubu); T. Mine, T. Makita, H. Mizuno, A. Kobori, T. Haruna, M. Takagi, T. Watanabe, N. Tanaka, H. Shimizu, T. Kurita, K. Motoki, N. Takeda, Y. Kijima, M. Ito, A. Nakata, Y. Ueda, A. Hirata, S. Kamakura, K. Satomi, T. Noda, Y. Yamada (Kansai); Y. Yoshiga, H. Ogawa, M. Kimura, T. Hayano, T. Kinbara, H. Tatsuno, M. Harada, K. F. Kusano, M. Adachi, A. Yano, M. Sawaguchi, J. Yamasaki, T. Matsuura, Y. Tanaka, H. Moritani, T. Maki, S. Okada, M. Takechi, T. Hamada (Chugoku); A. Nishikado, Y. Takagi, I. Matsumoto, T. Yamamoto, T. Soeki, Y. Doi, M. Okawa, H. Seo, S. Kitamura, K. Yamamoto, M. Akizawa, N. Kaname (Shikoku); S. Ando, S. Narita, T. Nakamura, T. Inou, Y. Fukuizumi, K. Saku, M. Ogawa, Y. Urabe, M. Ikeuchi, S. Harada, H. Yamabe, Y. Imamura, Y. Yamanouchi, K. Sadamatsu, K. Yoshida, T. Kubota, N. Takahashi, N. Makino, Y. Higuchi, T. Ooie, T. Iwao, K. Kitamura, T. Imamura, K. Maemura, N. Komiya, M. Hayano, H. Yoshida, K. Yamashiro, K. Kumagai (Kyushu).
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